Trial Profile
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- 15 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 protocol was amended to allow inclusion of additional patients randomized to the TLPLDC vaccine arm in a continuation trial in which patients received the same vaccine preparation method and dosing schedule
- 01 Oct 2021 Results of primary analysis for safety and efficacy published in the Annals of Surgical Oncology